Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786510 | 0.84 | THRB (0.35) | TSHRLMNA | |
| SCHEMBL5165058 | 0.81 | HCAR2 (0.31) | HCAR2TDP1 | |
| SCHEMBL3575191 | 0.78 | HDAC2 (0.35) | TSHRCHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1173061 | 0.77 | HDAC1 (0.40) | HCAR2LMNACHRM1AKR1A1CHRM3 | |
| SCHEMBL8206813 | 0.75 | — | — | |
| SCHEMBL3307713 | 0.74 | — | — | |
| SCHEMBL1172944 | 0.73 | HDAC1 (0.37) | HCAR2LMNACHRM1AKR1A1CHRM3 | |
| SCHEMBL9632890 | 0.72 | GPR84 (0.42) | TSHRHDAC2 | |
| SCHEMBL7566844 | 0.72 | HSD17B10 (0.32) | TSHRTDP1 | |
| SCHEMBL27730933 | 0.72 | HDAC1 (0.40) | HCAR2LMNACHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259992-A1 | Two-component adhesion promoter combination of an unsaturated alkoxysilane and a mercaptoalkyl alkoxysilane, for use in dental prostheses | 3M ESPE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| US-6833425-B1 | Filler for plastic formulations based on polyurethane | 3M ESPE AG (DE) | 2004-12-21 | — | — | US | disclosed |
| US-6767935-B1 | CATIONIC POLYMERIZATION OF UNSATURATED CARBONIC ACIDS, ANHYDRIDES OR ACID CHLORIDES, PHOSPHORIC OR PHOSPHONIC ACID OR ESTERS, SULFONIC ACIDS OR ESTERS; CURING | 3M ESPE AG (DE) | 2004-07-27 | — | — | US | disclosed |
| EP-1187594-A1 | SURFACE TREATMENT AGENT FOR LAMINATED FABRIC | 3M Espe AG (DE) | 2002-03-20 | — | — | EP | disclosed |
| EP-1141094-A1 | CYCLOSILOXANE-BASED CROSS-LINKABLE MONOMERS, PRODUCTION THEREOF AND USE THEREOF IN POLYMERISABLE MATERIALS | 3M Espe AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001037787-A1 | SURFACE TREATMENT AGENT FOR LAMINATED FABRIC | 3M ESPE AG (DE) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000042092-A1 | CYCLOSILOXANE-BASED CROSS-LINKABLE MONOMERS, PRODUCTION THEREOF AND USE THEREOF IN POLYMERISABLE MATERIALS | 3M ESPE AG (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259992-A1 | Two-component adhesion promoter combination of an unsaturated alkoxysilane and a mercaptoalkyl alkoxysilane, for use in dental prostheses | ITGA2, ITGB2, ITGA2B | HCAR2 599/4885TSHR 3882/4885LMNA 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.